Home » Newsletters » BioWorld Science

BioWorld Science

July 27, 2005

View Archived Issues

NIH accepts clinical study of Zestra

CombinatoRx and HenKan sign Asian agreement for CRx-026

Alexza Molecular Delivery changes name to Alexza Pharmaceuticals

Clinical evidence confirms the survival benefits of Provenge in advanced prostate cancer

ARIES-2 study of ambrisentan completes enrollment

ACT 3 atrial fibrillation study of RSD-1235 completes enrollment

Pivotal study of MBP-8298 expands into Europe

FDA requests information on phase II study of arimoclomol for ALS

Schwarz Pharma acquires remaining rights to rotigotine

Kirin Brewery acquires Hematech

XL-820 enters phase I study in solid tumors

ONO-4128 begins phase III trials in treatment-experienced HIV patients

Schering-Plough to acquire from Millennium exclusive U.S. Integrilin rights

Progress in NicOx ophthalmology collaboration with Pfizer

IGN-311 begins new study, subject of new Asian licensing agreement

M-2000: a novel, safe and efficacious NSAID for arthritis

Wockhardt reports successful progression of new quinolone into clinical trials

MC4 receptor agonist shows in vivo efficacy for obesity and sexual dysfunction

In vitro and in vivo effects of novel DPP-IV inhibitor KR-62436

NITD to test Alfacell's AC 03-636 for Dengue fever

FDA issues public health advisory for mifepristone

New agents for treating hepatitis C infection disclosed

Recent Sumitomo patent reports new treatments for skin and allergic diseases

Update on the antitumor efficacy and safety of pemetrexed

New clinical data on the survival effects of bexarotene in advanced NSCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...